Temple University, with local Emergency Medical Services and hospitals, is conducting RAMPART, a pre-hospital research study to identify which anti-seizure medication works best when given by paramedics.
-
What is RAMPART?
Status epilepticus, a condition of persistent seizures that do not stop, is a true neurologic emergency associated with significant death and disability. Paramedics treat status epilepticus with anti-seizure medicine, but giving medicine through a vein can be difficult or slow in a seizing patient. This study will determine (1) if the anti-seizure drug midazolam given as a shot in the muscle stops seizures as well as the anti-seizure medicine lorazepam given directly into a vein, and (2) the rapidity and safety of these two medicines given in these different ways. The RAMPART study will be conducted using special rules for studies in which the subjects are too sick or incapacitated to either agree to or decline to participate at the time they are being treated in the ambulance or in the Emergency Room.To learn more about these rules, referred to as "exception from informed consent for emergency research" click here.
- What is community consultation and public disclosure (CC/PD)?
- Part of the EFIC (exception from informed consent) process is releasing study information to the community in which the study will be deployed. This allows the community to provide feedback, ask questions, share comments and opt out of inclusion in the study.
- Our IRB approved CC/PD for RAMPART includes:
|
